Is negative schizophrenia a variant of parkinsonism?

References

• Alpert M., Rush M. Comparison of affects in Parkinson's disease and schizophrenia. Psycho-pharmacology Bulletin 1983; 196: 118–120
   Google Scholar
• Alvord E. E., Forno L. S. Pathology. Handbook of Parkinson's disease, W. C. Roller. Marcel Dekker, Inc., New York 1987; 209–236
   Google Scholar
• Andreasen N. C. Positive vs. negative schizophrenia: A critical evaluation. Schizophrenia Bulletin 1985; 11: 380–389
   PubMed Web of Science ®Google Scholar
• Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamines and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 1980; 72: 17–19
   PubMed Web of Science ®Google Scholar
• Angrist B., Peselow E., Rubinstein M. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology 1982; 78: 128–130
   PubMed Web of Science ®Google Scholar
• Birkmayer W., Knoll J., Riederer P., Youdim M. B.H.Hars V., Kim Y. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: A longterm study. Journal of Neural Transmission 1985; 64: 113–127
   PubMed Web of Science ®Google Scholar
• Boiler F., Passafiume D., Keefe N. C.Rogers K., Morrow L., Kim Y. visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors. Archives of Neurology 1984; 41: 485–490
   PubMedGoogle Scholar
• Bowman M., Lewis M. S. Sites of subcortical damage in diseases which resemble schizophrenia. Neuropsychologiu 1980; 18: 597–601
   PubMed Web of Science ®Google Scholar
• Carpenter W. T., Heinrichs D. W., Alphs L. D. Treatment of negative symptoms. Schizophrenia Bulletin 1985; 11: 440–452
   PubMed Web of Science ®Google Scholar
• Christensen E., Moller J. E., Fauerbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatrica Scandinavica 1970; 46: 14–23
   PubMed Web of Science ®Google Scholar
• Crow T. J., Johnstone E C., McClelland H. A. The coincidence of schizophrenia and Parkinsonism: some neurochemical implications. Psychological Medicine 1976; 6: 227–233
   PubMed Web of Science ®Google Scholar
• Crow T. J. Is schizophrenia an infectious disease?. Lancet 1983; 1: 173–175
   PubMed Web of Science ®Google Scholar
• Desai N. G., Ganghadhar B. N., Pradhan N., Channabasavanna S. M. Treatment of negative schizophrenia with d-amphetamine. American Journal of Psychiatry. 1984; 141: 723–724
   PubMed Web of Science ®Google Scholar
• Economo C. Encephalitis Lethargica-Ils Sequelae and Treatment, K. O. Newman. University Press, Oxford 1931
   Google Scholar
• Fairweather D. S. Psychiatric aspects of the postencephalitic syndrome. Journal of Mental Science 1947; 93: 201–254
   PubMed Web of Science ®Google Scholar
• Friedhoff A. J. A strategy for developing novel drugs for the treatment of schizophrenia. Schizophrenia Bulletin 1983; 9: 555–562
   PubMed Web of Science ®Google Scholar
• Friedman J. H., Lannon M. C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39: 1219–1221
   PubMed Web of Science ®Google Scholar
• Green M., Walker E. Neuropsychological performance and positive and negative symptoms in schizophrenia. Journal of Abnormal Psychology 1985; 94: 460–469
   PubMed Web of Science ®Google Scholar
• Hoehn M. M., Crowley T J., Rutledge C O. Dopamine correlates of neurological and psychological status in untreated parkinsonism. Journal ofneurlogy, Neurosurgery and Psychiatry 1976; 39: 941–951
   PubMed Web of Science ®Google Scholar
• Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic-induced parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22, All-W)
   Web of Science ®Google Scholar
• Hollister L. E., Glazener F. S. Concurrent paralysis agitans and schizophrenia. Diseases of the Nervous System 1961; 22: 187–189
   PubMedGoogle Scholar
• Howard R. S., Lees A. J. Encephalitis lethargica. A report of four recent cases. Brain 1987; 110: 19–33
   PubMed Web of Science ®Google Scholar
• Kay S. R., Opler L. A. L-dopa in the treatment of negative schizophrenic symptoms. International Journal of Psychiatry in Medicine 1985; 15: 293–298
   PubMed Web of Science ®Google Scholar
• Kay S. R., Opler L. A., Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. British Journal of Psychiatry 1986; 149: 439–448
   PubMed Web of Science ®Google Scholar
• Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–275
   PubMed Web of Science ®Google Scholar
• Lesch A., Bogerts B. The diencephalon in schizophrenia: Evidence for reduced thickness of the periventricular grey matter. European Archives of Psychiatry and Neurological Sciences 1984; 234: 212–219
   PubMedGoogle Scholar
• Loranger A. W., Goodell H., McDowell F. H., Lee J. E., Sweet R. D. Intellectural impairment in Parkinson's syndrome. Brain 1972; 95: 405–412
   PubMed Web of Science ®Google Scholar
• Luchins D. J., Jackman H., Meltzer H. Y. Lateral ventricular size and drug-induced Parkinsonism. Psychiatry Research 1983; 9: 9–16
   PubMed Web of Science ®Google Scholar
• MacKay A. V.P. Positive and negative schizophrenic symptoms and the role of dopamine. Discussion, 1. British Journal of Psychiatry 1980; 137: 379–383
   PubMed Web of Science ®Google Scholar
• McCowan P. K., Cook L. C. The mental aspect of chronic epidemic encephalitis. Lancet 1928; 1: 1316–1320
   Google Scholar
• Nieto D., Escobar A. Major Psychoses. Pathology of the Nervous System, J. Minckler. McGraw-Hill Book Co., New York 1972; vol. 3: 2654–2665
   Google Scholar
• Nyback H., Berggren B., Hindmarsh T., Sedvall G., Wiesel F. Cerebroventricular size and cerebrospinal fluid monoamine metabolite in schizophrenic patients and healthy volunteers. Psychiatry Research 1983; 9: 301–308
   PubMed Web of Science ®Google Scholar
• Pakkenberg H., Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurologica Scandinavica 1986; 73: 295–297
   PubMed Web of Science ®Google Scholar
• Pirozzolo F. J., Hansch E. C., Mortimer J. A. Dementia in Parkinson disease: A neuropsychological analysis. Brain and Cognition 1982; 1: 71–83
   PubMedGoogle Scholar
• Redmond D. E., Maas J. W., Kling A., Dekirmenjian H. Changes in primate social behavior after treatment with alpha-methyl-para-tyrosine. Psychosomatic Medicine 1971; 33: 97–113
   PubMed Web of Science ®Google Scholar
• Rifkin A. The risks of longterm neuroleptic treatment of schizophrenia: Especially depressive and akinesia. Acta Psychiatrica Scandinavica, suppl 1981; 61: 129–134
   Google Scholar
• Rifkin A., Quitkin F., Klein D. F. Akinesia: A poorly recognized drug-induced extrapyramidal behavioral disorder. Archives of General Psychiatry 1975; 32: 672–674
   Web of Science ®Google Scholar
• Sandyk R., Kay S. R. Interpretation of the positive-negative distinction. Positive and negative syndromes in schizophrenia: assessment and research, S. R. Kay. Brunner/Mazel, New York, in press a
   Google Scholar
• Sandyk R., Kay S. R. Bradykinesia is associated with ventricular enlargement in chronic schizophrenia. International Journal of Neuroscience, in press b
   Google Scholar
• Sandyk R., Kay S. R. Habituation of the glabellar tap reflex as a marker of negative schizophrenia. International Journal of Neuroscience, in press c
   Google Scholar
• Sandyk R., Kay S. R. Negative schizophrenia and Seborrhea: Possible role of hypothalamic dysfunction in the pathophysiology of the negative syndrome. International Journal of Neuroscience, in press a
   Google Scholar
• Scholz E., Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. European Archives of Psychiatryand Neurological Sciences 1985; 235: 60–64
   PubMedGoogle Scholar
• Sommers A. A. “Negative symptoms”: conceptual and methodological problems. Schizophrenia Bulletin 1985; 11: 364–379
   PubMed Web of Science ®Google Scholar
• Steiner I., Gomori J. M., Melamed E. Features of brain atrophy in Parkinson's disease: A CT scan study. Neuroradiology 1985; 27: 158–160
   PubMed Web of Science ®Google Scholar
• Stern Y. Behavior and the basal ganglia. The Dementias, R. Maye, W. G. rosen. Raven Press, New York 1983; 195–209
   Google Scholar
• Stevens J. Neuropathology of schizophrenia. Archives of General Psychiatry 1982; 39: 1131–139
   PubMed Web of Science ®Google Scholar
• Tandon R., Greden J. F. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry 1989; 46: 745–753
   PubMed Web of Science ®Google Scholar
• Tetrud J. W., Langston J. W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519–522
   PubMed Web of Science ®Google Scholar
• Van Kammen D. P., Mann L. S., Sternberg D. E., Ninan P. T., Marder S. R., van Kammen D. B., Rieder R. O., Linnoila M. Dopamine beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. Science 1983; 220: 974–977
   PubMed Web of Science ®Google Scholar
• Van Kammen D. P., van Kammen W. B., Mann L. S., Seppala T., Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Archives of General Psychiatry 1986; 43: 978–983
   PubMed Web of Science ®Google Scholar
• Van Putten T., May P. R.A. “Akinetic depression” in schizophrenia. Archives of General Psychiatry 1978; 35: 1101–1107
   PubMed Web of Science ®Google Scholar
• Van Putten T., May P. R.A., Wilkins J. N. Importance of akinesia: Plasma chloropromazine and prolactin levels. American Journal of Psychiatry 1980; 137: 1446–1448
   PubMed Web of Science ®Google Scholar
• Woodard J. S. Concentric hyaline inclusion body formation in mental disease analysis of twenty-seven cases. Journal of Neuropathology and Experimental Neurology 1962; 21: 442–449
   PubMed Web of Science ®Google Scholar
• Zigmond M. J., Acheson A. L., Stachowiak M. K., Strickerm E. M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Archives of Neurology 1984; 41: 856–861
   PubMedGoogle Scholar